In the Reply Letter titled “Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome—Reply,” published in the April 26, 2022, issue of JAMA, a sentence was incorrectly worded. In the second to last paragraph, the last sentence should have been “Beyond the surfactant received as part of the minimally invasive surfactant therapy intervention, in both groups any other surfactant therapy given followed accepted guidelines in relation to dosage, timing, and Fio2 threshold.” This article was corrected online.
Source: JAMA Online First